Oppenheimer downgraded respiratory device maker ResMed (NYSE:RMD) to Perform from Outperform on Tuesday, citing an “air pocket” for the stock in the wake of encouraging data for Eli Lilly’s (NYSE:LLY) ...

ResMed Inc. company and executive profile by Barron's. View the latest RMD company infomation and executive bios.

Eli Lilly and Company released data in regards to a potential treatment for obstructive sleep apnea. Lilly's potential treatment achieved all primary and secondary endpoints. Unlock your all-in-one ...

Two digital health companies focused on sleep published data this week that highlighted the efficacy of their respective platforms, bringing continued attention to the space after a CES week where ...

ResMed is partnering with Providence St. Joseph to give clinicians insights into helping patients be more compliant, says ResMed's VP of SaaS Strategy Annie McBride.

ResMed (RMD) stock is currently at a fascinating juncture. It is trading at a low price, and if you decide to invest in it, you are wagering on a ...

Shares of ResMed Inc. RMD rallied 2.78% to $252.55 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 0.05% to 6,836.17 and ...